← Back to Home

Finding New Drug Targets Through Disease Differences: AstraZeneca Partners with insitro to Study Hepatitis and Cardiomyopathy

Patients with the same diagnosis may have different disease mechanisms. AstraZeneca and insitro will use AI to explore these differences. The collaboration remains at the drug discovery stage, with no evidence of clinical efficacy yet.

By SURL BioNews

Finding biological signals associated with a disease is still some distance from identifying drug targets that can alter its course. A new collaboration between AstraZeneca and insitro aims to explore biological differences between patients to identify therapeutic directions for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathy.

Medical Marketing & Media mentioned this AI drug discovery initiative in its industry roundup on October 16, 2026. According to details released by insitro the previous day, the companies signed a globally exclusive research collaboration agreement under which insitro will use its Virtual Human platform to explore disease-causing biology and advance targets designated by AstraZeneca through development candidate selection. AstraZeneca will be responsible for subsequent clinical development, regulatory affairs, and commercialization.

The research starts with disease heterogeneity: even patients with the same diagnosis may have different underlying biological mechanisms. The collaboration aims to use AI to analyze complex human data, identify which differences may drive disease, and select intervention strategies accordingly, rather than merely identifying signals that accompany disease.

However, “identifying causality” currently reflects the company’s description of the platform’s capabilities and research objectives. The announcement did not provide the size of the datasets used in this collaboration, the patient composition, or model validation results, nor did it name any targets or drug candidates. The available information is therefore insufficient to determine whether the platform can reliably distinguish patient populations or improve drug development success rates.

The deal terms show the pharmaceutical company’s willingness to invest in early discovery, but the payment structure also reflects the uncertainty of research and development. According to insitro’s announcement, the company will receive a $40 million upfront payment, with up to approximately $1.46 billion in potential milestone payments, plus single-digit percentage royalties on future global sales. The milestone amounts are not realized revenue.

The collaboration’s next substantive test is whether it can turn clues derived from data analysis into disease mechanisms that can be validated and targeted with drugs. Even if drug candidates are selected, they will still need to undergo clinical trials and regulatory review to determine which patients benefit and whether the benefits outweigh the risks.

References

  1. Medical Marketing & Media
  2. STAT
  3. GBH
  4. insitro